Back to Directory

Brookie M Best

Email

brookie@ucsd.edu

Phone

(858) 822-5550

Institution

University of California, San Diego

Title

Associate Clinical Professor

Address

University of California, San Diego
Schools of Medicine and Pharmacy
9500 Gilman Drive, MC 0657
La Jolla, CA 92093-0657
United States of America

Request an Update

Affiliated Studies

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

DAIDS Number

30070

Research Area

Treatment

Study Status

In Development

P1111: Safety, Tolerability and PK of Rilpivirine

DAIDS Number

11902

Research Area

Antiretroviral Strategies

Study Status

Withdrawn

Locality

US & Non-US

IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection

DAIDS Number

20734

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

Locality

US & Non-US

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Closed to Accrual

Locality

US & Non-US

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Treatment

Study Status

Enrolling

Locality

US & Non-US

Show All